Solve Therapeutics, Inc

Solve is developing novel antibody-drug conjugates (ADCs) engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics. Our team’s approach to ADCs is built on our foundational understanding of how the components of the molecule – antibody, linker, and payload – can be optimized and work together synergistically to meaningfully improve the benefit-risk profile for patients. ADCs have proven clinical value, but issues remain with off-target toxicity, sub-optimal payload delivery, and difficulties with patient selection. Solve’s technologies are designed to address these challenges through cutting-edge antibody engineering, a novel hydrophilic and highly stable linker system (CloakLink™), and an integrated diagnostic platform designed to help identify patients most likely to benefit from treatment.